Skip to main content

Market Overview

Cytokinetics Presents Exploratory Analyses of Data from Phase 3 Clinical Trial of Dexpramipexole in Patients with ALS

Share:

Cytokinetics, Inc. (Nasdaq: CYTK) today announced the presentation of exploratory analyses of data from EMPOWER, a Phase 3 clinical trial of dexpramipexole in patients with ALS, which demonstrated the rate of decline of slow vital capacity (SVC) predicts the risk of meaningful clinical events, including a decline in the three respiratory questions of the ALSFRS-R, as well as the time to the first occurrence of respiratory insufficiency, tracheostomy or death.  Data from placebo-treated patients in EMPOWER were provided to Cytokinetics by Knopp Biosciences.  The analyses were presented recently at the 6th Annual California ALS Research Summit in La Jolla, California.
Vital capacity measures the amount of air expelled from the lungs after a maximum inhalation and is used to assess the strength of the skeletal muscles responsible for breathing (e.g., the diaphragm). Vital capacity is often expressed in terms of the percentage of the normal value predicted for the individual patient's sex, age, and height; i.e., percent predicted vital capacity.  It has been shown to be an important predictor of disease progression and survival in previous clinical trials in patients with ALS who typically die of

See full press release

 

Related Articles (CYTK)

View Comments and Join the Discussion!

Posted-In: News Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com